Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Heng Score for Metastatic Renal Cell Carcinoma (RCC) Prognosis

    Determines overall survival in patients treated with VEGF–targeted therapy.
    Favorite
    When to Use
    Pearls/Pitfalls
    Why Use

    Patients with mRCC treated with modern VEGF therapy.

    This score placed subjects with metastatic renal cell carcinoma (mRCC) treated with modern VEGF therapies (e.g. sunitinib) into three survival groups: poor, intermediate, and favorable. Both the derivation and validation are chart review studies; however, both found similar results. Prospective validation is eagerly awaited.

    There are no validated scoring systems for predicting survival in mRCC. Using a score may help sketch categories of survival time better than clinical judgment alone.

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    The Heng score (Database Consortium Model) has theoretical advantages over some other scores:

    • A successful validation study.
    • Focus on those receiving modern treatments in common practice.

    While the score has not been shown to be accurate in any prospective study it may be among the most likely to correctly predict survival categories.

    Management

    We are unaware of validated management algorithms using the score.

    Critical Actions

    The Heng score is relevant exclusively to mRCC patients undergoing VEGF therapy.

    Dr. Daniel Heng

    About the Creator

    Daniel Heng, MD, is a clinical associate professor of medicine at the University of Calgary and practicing medical oncologist at the Tom Baker Cancer Center in Calgary. Dr. Heng is currently the chair of the Genitourinary Tumor Group in Calgary and is the chair of the International Metastatic Renal Cell Cancer Database Consortium. His research focuses on outcomes, prognostic factors, and clinical trials metastatic renal cell carcinoma and other genitourinary malignancies.

    To view Dr. Daniel Heng's publications, visit PubMed